Therapeutics
Developing Next Generation Therapeutics for Healthy Life
Porustobart HBM4003
CTLA-4
Melanoma, HCC*, RCC* & Other Advanced Solid Tumors
Melanoma, HCC*, NEC/NET* & Other Advanced Solid Tumors
NSCLC* & Other Advanced Solid Tumors
Global
Global
Global
HBM7008
B7H4x4-1BB
Solid Tumors
Ex-U.S. 1
HBM7022
CLDN18.2xCD3
Solid Tumors
Global License to AstraZeneca
HBM1022
CCR8
Solid Tumors
Global
HBM1020
B7H7
Solid Tumors
Global
HBM1007
CD73
Solid Tumors
Global
HBM9033
MSLN ADC
Solid Tumors
Global
HBM9027
PD-L1xCD40
Solid Tumors
Global
HBM1047
CD200R1
Solid Tumors
Global
HBM7004
B7H4×CD3
Solid Tumors
Global
HBM9014
LIFR
Solid Tumors
Global
Batoclimab HBM9161(HanAll)
FcRn
MG*
TED*
Greater China License to CSPC
Greater China License to CSPC
HBM9378
TSLP
Asthma
Global
HBM9022(AbbVie; Utrecht University; Erasmus MC)
SARS-COV-2
COVID-19
Global License to AbbVie
HBM
Partner
Registrational Clinical Trial
Monotherapy
PD1 / Chemo
Breakthrough Therapy Designation
* HCC = Hepatocellular Carcinoma
* RCC = Renal Cell Carcinoma
* NEC = Neuroendocrine Carcinoma
* NET = Neuroendocrine Tumour
* NSCLC = Non-Small Cell Lung Cancer
* MG = Myasthenia Gravis
* TED = Thyroid Eye Disease
* The U.S. rights of HBM7008 is out-licensed to Cullinan Oncology in February 2023